Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Fernando G Vieira"'
Autor:
Fernando G Vieira, Valerie R Tassinari, Joshua D Kidd, Andrew Moreno, Kenneth Thompson, Steven Perrin, Alan Gill, Theo Hatzipetros
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0292190 (2024)
Amyotrophic lateral sclerosis (ALS) has been linked to overactivity of the protein kinase RNA-like ER kinase (PERK) branch of the unfolded protein response (UPR) pathway, both in ALS patients and mouse models. However, attempts to pharmacologically m
Externí odkaz:
https://doaj.org/article/3f43e16213ce47a18658414260f2a41c
Autor:
Fernando G Vieira, Qinggong Ping, Andy J Moreno, Joshua D Kidd, Kenneth Thompson, Bingbing Jiang, John M Lincecum, Monica Z Wang, Gerard S De Zutter, Valerie R Tassinari, Beth Levine, Theo Hatzipetros, Alan Gill, Steven Perrin
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135570 (2015)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons. The mechanisms leading to motor neuron degeneration in ALS are unclear. However, there is evidence for involvement of endoplasmic r
Externí odkaz:
https://doaj.org/article/f052d1fb3a364d89b9b51dacb83c5f26
Autor:
Fernando G Vieira, Eva LaDow, Andy Moreno, Joshua D Kidd, Beth Levine, Kenneth Thompson, Alan Gill, Steven Finkbeiner, Steven Perrin
Publikováno v:
PLoS ONE, Vol 9, Iss 12, p e91608 (2014)
Treatment options for people living with amyotrophic lateral sclerosis (ALS) are limited and ineffective. Recently, dexpramipexole (RPPX) was advanced into human ALS clinical trials. In the current studies, we investigated RPPX in two parallel screen
Externí odkaz:
https://doaj.org/article/b2f5a8bfa5d94825bb4e8c5d5954e8a7
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 17 (2023)
IntroductionIntronic repeat expansions in the C9orf72 gene are the most frequent known single genetic causes of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These repeat expansions are believed to result in both loss-of-func
Externí odkaz:
https://doaj.org/article/923b09c8034a407e887177a22f52d0e7
Autor:
Fernando G. Vieira, Subhashini Venugopalan, Alan S. Premasiri, Maeve McNally, Aren Jansen, Kevin McCloskey, Michael P. Brenner, Steven Perrin
Publikováno v:
npj Digital Medicine, Vol 5, Iss 1, Pp 1-9 (2022)
Abstract Amyotrophic Lateral Sclerosis (ALS) disease severity is usually measured using the subjective, questionnaire-based revised ALS Functional Rating Scale (ALSFRS-R). Objective measures of disease severity would be powerful tools for evaluating
Externí odkaz:
https://doaj.org/article/f020b25d7ebb4e21a10ad430ce2cc01b
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 15 (2021)
Hexanucleotide repeat expansion (G4C2n) mutations in the gene C9ORF72 account for approximately 30% of familial cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as well as approximately 7% of sporadic cases of ALS. G4C2
Externí odkaz:
https://doaj.org/article/4fdaeadbb65d4fce9f287eba6cd78ee3
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 15 (2021)
Frontiers in Cellular Neuroscience
Frontiers in Cellular Neuroscience
Hexanucleotide repeat expansion (G4C2n) mutations in the gene C9ORF72 account for approximately 30% of familial cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), as well as approximately 7% of sporadic cases of ALS. G4C2
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is a repeat expansion mutation in the C9orf72 gene. Repeat-associated non-AUG (RAN) translation of this expansion produces five species of dipeptid
Publikováno v:
International Journal of Molecular Sciences
Volume 20
Issue 24
Volume 20
Issue 24
A repeat expansion mutation in the C9orf72 gene is the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In this study, using multiple cell-based assay systems, we reveal both increased dipeptid
Autor:
Alan Gill, Fernando G. Vieira, Michael H. Rivner, Valerie R. Tassinari, Namita Goyal, Nazem Atassi, Daniela L. Grasso, Ericka Simpson, Sabrina Paganoni, James D. Berry, Nicte I. Mejia, Farrah J. Mateen, Eric A. Macklin, Stanley H. Appel, Steven Perrin
Publikováno v:
Muscle & Nerve. 56:1077-1084
INTRODUCTION: Immune activation is implicated in ALS progression. Oral fingolimod reduces circulating lymphocytes. The objective of this phase IIa randomized controlled trial was to test the short-term safety, tolerability, and target engagement of f